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Abstract: Ferrochelatase (FECH) activity is decreased in erythropoietic protoporphyria (EPP), causing increased production 
and excretion of protoporphyrin. This study examined whether the level of expression of the nonmutant FECH allele is a 
determinant of phenotype in a mouse model of EPP that carries a heterozygous deletion of exon 10 in FECH. Two mice 
strains that had a two-fold difference in FECH mRNA levels in bone marrow and liver (low expressing C3H/HeJ and high 
expressing CBA/J) were used to establish congenic strains containing the mutation. Erythrocyte protoporphyrin levels in 
C3H/HeJ heterozygous mice were signiﬁ  cantly higher than in their wildtype littermates, whereas levels in CBA/J hetero-
zygous mice did not differ signiﬁ  cantly from their wildtype littermates. Biliary excretion of protoporphyrin was also sig-
niﬁ  cantly higher in C3H/HeJ heterozygous mice. The levels of normal FECH mRNA in bone marrow measured by real 
time PCR were 138 +/− 30 copies per ug total RNA in C3H/HeJ +/− mice, 320 +/− 59 in C3H/HeJ +/+ mice and 634 +/− 
38 in CBA/J +/+ mice. Levels in liver tissue of the mice differed signiﬁ  cantly in the same pattern. Thus, the level of expres-
sion of the nonmutant FECH allele is a determinant of phenotype in a mouse model of EPP as has been demonstrated in 
human EPP.
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Introduction
Erythropoietic protoporphyria (EPP) is a genetic disorder of porphyrin metabolism in humans that was 
ﬁ  rst described in 1961 by Magness and co-workers when they reported a man with lifelong sensitivity 
to sunlight and increased protoporphyrin levels in erythrocytes and feces (Magness et al. 1961). 
Photosensitivity, which is the major clinical feature, results from the photoactive damage of protopor-
phyrin to skin (Timonen et al. 2000). Some patients also develop hepatobiliary disease due to proto-
porphyrin induced damage to liver structure and function (Doss and Frank, 1989). This may progress 
to liver failure and necessitate liver transplantation (McGuire et al. 2005).
A deﬁ  ciency of ferrochelatase (FECH, EC4.99.1.1) activity underlies the excessive production and 
excretion of protoporphyrin in EPP (Bonkovsky et al. 1975). FECH, which is the last enzyme in the 
heme biosynthesis pathway, is located on the matrix side of the inner mitochondrial membrane and 
catalyzes the insertion of ferrous iron into protoporphyrin to form heme (Dailey et al. 2000). All heme 
forming tissues may potentially contribute to the excess formation of protoporphyrin in EPP, with the 
bone marrow being the major source (Poh-Fitzpatrick, 1985). The functional human FECH enzyme is 
a homodimer that contains two NO sensitive and coordinated 2Fe-2S clusters (Wu et al. 2001). The 
FECH gene contains 11 exons, and FECH mRNA has an open reading frame of 1269 bases that encodes 
a protein of 423 amino acid residues (Nakahashi et al. 1990). There is a single transcript with 2 poly-
adenylation sites in erythroid and non-erythroid cells, indicating there is only one FECH gene in heme 
forming tissues (Taketani et al. 1992).
Patients with EPP are usually heterozygous for a FECH mutation, even those with severe disease, 
and extensive genetic heterogeneity has been noted (Wang et al. 1994; Rufenacht et al. 1998). The gene 
mutations by themselves do not account for disease expression, as they cause only minimally increased 
protoporphyrin overproduction (Chen et al. 2002). Thus most individuals with symptomatic disease 
also have a polymorphism in intron 3 of the nonmutant FECH allele (IVS3-48c) that lowers gene 
expression (Gouya et al. 2002; Risheg et al. 2003).234
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The purpose of this study was to examine 
whether the level of expression of the nonmutant 
FECH allele is also a determinant of phenotype in 
a mouse model of EPP, using mice in which an 
exon 10 deletion of FECH had been introduced 
into the genome of mouse embryonic stem cells 
by homologous recombination (Magness and 
Brenner, 1999; Magness et al. 2002).
Methods
Selection and breeding of Mice
Magness and Brenner provided mice carrying the 
exon 10 deletion, along with a neomycin resistant 
cassette in the same allele (Magness et al. 2002). 
Primers were designed to hybridize with this cas-
sette, and PCR ampliﬁ  cation of genomic DNA 
from animals with the exon 10 deletion produced 
a product that was identiﬁ  ed by ethidium bromide 
stain on agarose gel, whereas genomic DNA from 
wild-type animals did not produce the product. 
Wild-type strains were selected on the basis of 
FECH gene expression as assessed by the level of 
FECH mRNA in liver and bone marrow, using 
relative quantitative RT-PCR as previously 
described (Risheg et al. 2003). Mice from ﬁ  ve dif-
ferent strains were evaluated (Table 1). Based on 
the results, CBA/J mice were selected as a high 
expressing strain and C3H/HeJ mice as a low 
expressing strain. FECH cDNA and 1000 bases of 
the FECH gene promoter and 5’ untranslated 
region of the two mice strains were sequenced, and 
no differences were found. Intron 3 was also 
sequenced, and both strains had base t at position -48. 
Thus it is likely that the difference in FECH expres-
sion in the two strains is caused by transacting 
factors and/or modiﬁ  er genes, not by a difference 
in FECH gene sequence.
In order to produce congenic strains, male off-
spring carrying the exon 10 deletion were back-
crossed with wild-type female C3H/HeJ and 
CBA/J mice through 7–9 generations. Breeding of 
the mice was carried out in the University of Ala-
bama at Birmingham Genetic Engineered Mouse 
Breeding Facility. The biochemical phenotype of 
heterozygous adult mice (3–6 months old) and their 
wild-type littermates was assessed by measurement 
of 1) erythrocyte protoporphyrin level; 2) total 
porphyrin level and ﬂ  uorescence peak in bile; 3) 
FECH enzyme activity in liver. The normal FECH 
mRNA level in bone marrow and liver was 
measured by quantitative real time PCR. Statistical 
analysis was done by the students T test and 
Wilcoxin/Kruskal-Wallis test.
Biochemical measurements
Protoporphyrin levels in erythrocytes were measured 
by spectroﬂ  ourometry after solvent partitioning 
(Morton et al. 1988; Bloomer et al. 1998). The 
level and ﬂ  uorescence peak of porphyrin in bile 
was assessed by spectroﬂ  ourometry after dissolving 
the bile in perchloric acid methanol (Morton et al. 
1988; Bloomer et al. 1998). Bile was obtained from 
gallbladders of the mice at the time of sacriﬁ  ce.
The level of FECH activity in whole liver 
homogenates was measured by Zn-deuteroporphyrin 
formation in pmol per second per mg protein 
(Bloomer et al. 1998).
Quantitative measurement of FECH 
mRNA by real-time PCR
The level of FECH mRNA was measured in total 
RNA extracted from whole liver tissue and from 
bone marrow of leg bones of the adult mice. Only 
the level of the wild-type (normal) species of FECH 
mRNA was measured in wild-type mice and mice 
heterozygous for the exon 10 deletion in FECH gene. 
The mutant species of FECH mRNA was not 
measured. The method used the Quantitect™ custom 
assay developed by Qiagen (Valencia, CA).
In order to develop the standard curve for the 
assay, RNA was extracted from mouse liver, and 
a 484 bp FECH amplicon (from exon 7 to exon 
11) was generated by RT-PCR. The primer 
sequences were sense, TCATCCAGTGCTTTG-
CAGAC; antisense, AGCTTGTTGGACTGGAT-
GTG. The amplicon was puriﬁ  ed on silica column 
Table 1. FECH mRNA in different mice strains.
Strain  FECH mRNA ÷ 18S RNA (%)
 bone  marrow  liver
C3H/HEJ 36.9  ± 11.6  53.7 ± 5.8
129/SvEvJ 44.4  ± 5.1  62.3 ± 6.6
DBA/2J 54.4  ± 3.8  37.3 ± 4.4
BAIB/cBy 67.5  ± 8.1  50.3 ± 15.8
CBA/J 80.0  ± 16.2  126.8 ± 13.2
Mean ± SEM for 6 mice in each group.
FECH DNA sequence in C3H/HeJ and CBA/J mice.
1. same sequence for FECH cDNA.
2.   same sequence for proximal 1000 bases of 5'—untranslated region 
of FECH gene.
3. same base at position IVS3-48 (thymine).235
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(QIA quick PCR puriﬁ  cation, Qiagen) and cloned 
into pCRS.1 vector (Invitrogen). Ligated fragments 
were placed in DH5a competent cells (Life Tech-
nologies). Plasmid DNA was prepared and the 
cloned amplicons were sequenced; cDNA plasmid 
concentrations were measured by optical density 
spectrophotometry (Spectronic Genesys 5). Copy 
number determination was calculated using the 
following formula: Copies/ml = 6.023 × 10
23 × 
[C] × OD260/molecular weight Where [C] = 5 × 
10
−5 g/ml for DNA; Molecular weight of the PCR 
product = number base pairs × 6.58 × 10
2. Serial 
dilutions from the cDNA plasmid were used as 
standard curves.
Primers and probes were designed by Qiagen 
Quantiprobe Design Software (Qiagen). The 
probe was designed to locate in exon 10 for spe-
ciﬁ  c detection of wild-type FECH mRNA. The 
probe sequence was ATCAGAAGAGCGGAGT 
with ﬂ  uorophone at the 3’ end and nonﬂ  uorescent 
quencher and minor grove binder (MGB) at the 
5’ end. The PCR primers yield a 93-nt amplicon 
from wild-type FECH with one primer speciﬁ  c 
to exon 9/10 fusion region and one primer speciﬁ  c 
to exon 11. Real-time PCR was performed on an 
ABI prism 7700 sequence detection system 
(Applied Biosystems). PCR conditions were 95 ºC 
for 15 min, 40 cycles at 94º for 15s, 56 ºC for 30s 
and 76 ºC for 30s. Each 50 µl reaction contained 
25 µl 2x QuantiTect probe PCR Master Mix, 
2.5 µl 20x primer mix, 2.5 µl 20 × Quantiprobe 
Solution and template cDNA. Each sample was 
run in triplicate. Standard wells contained 4000, 
2000, 1000, 500, 200, 100, 50 and 10 copies of 
plasmid FECH cDNA.
DNA microarray analysis of bone 
marrow gene expression
Microarray analysis of bone marrow gene expres-
sion in C3H/HeJ mice and CBA/J mice was done 
using the GeneChip® Mouse Expression Set 430 
(Affymetrix, Santa Clara, CA). Bone marrow was 
obtained from leg bones of 3 adult male mice and 
pooled as a single sample. Three samples were 
prepared for the two mice strains, total RNA was 
isolated by TRIzol reagent (Life Technologies, 
Rockville, MD) from each of the 6 samples, and 
2 ug of total RNA from each sample was submitted 
to the Microarray Shared Facility for Affymetrix 
Gene Chip Analysis, University of Alabama at 
Birmingham Comprehensive Cancer Center.
The details of the procedures used in the 
analysis are presented in the manufacturer’s 
technical manual (Affymetrix). In brief, the qual-
ity of the RNA was determined using the RNA 
Nano Chip on the Agilent BioAnalyzer before 
synthesis of double-strand cDNA. Double-strand 
cDNA was generated by linear ampliﬁ  cation using 
an oligo dT-T7 primer and reverse transcriptase 
(RT). Biotin labeled cRNA was then synthesized 
by in vitro transcription (IVT) using the 3'-Ampli-
ﬁ  cation Reagents for IVT labeling (Affymetrix). 
The quality of the cRNA was determined on the 
Agilent BioAnalyzer before it was fragmented into 
50 to 200 base fragments. Prior to hybridization 
to the expression arrays, the quality of the hybrid-
ization target was determined by hybridization to 
a Test3 array. The result indicated the efﬁ  cacy of 
the RT/IVT reaction by the ratios of expression 
level of 5' to 3' of the housekeeping genes β-actin 
and GAPDH. If the quality of the hybridization 
target passed the quality parameters from the Test3 
array, the expression arrays were hybridized over-
night at 45 ºC and then washed, stained, and 
scanned on the following day. Gene expression 
levels were extracted using the Gene Chip Operat-
ing Software. Comparisons were made of bone 
marrow gene expression for each of the 3 CBA/J 
samples with each of the 3 C3H/HeJ samples to 
determine the fold change for each transcript 
(9 total comparisons).
For microarray data analysis and annotation, 
the software packages GeneTrafﬁ  c (Iobio/Strat-
age/Agilent, Inc. Santa Clara, CA) and ArrayAssist 
Enterprise together with PathwayAssist (Strata-
gene/Agilent, Santa Clara, CA) were used. Brieﬂ  y, 
the raw Genechip ﬁ  les from GCOS were uploaded, 
background-subtracted, and normalized with GC-
RMA method (Gentleman et al. 2004). The control 
group was used as a baseline to calculate the inten-
sity ratio/fold changes of the treated group versus 
the control group. The ratio was log2-transformed 
before further statistical analysis. The p-values 
were obtained by an unpaired t-test assuming 
unequal variance.
Results
Levels of erythrocyte protoporphyrin in adult 
(3–6 months old) heterozygous C3H/HeJ mice 
were signiﬁ  cantly higher than in C3H/HeJ wild-
type mice, CBA/J heterozygous mice and CBA/
J wildtype mice (Table 2). There was no signiﬁ  -236
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cant difference noted between male and female 
mice in the same strain. Bile porphyrin levels in 
the heterozygous C3H/HeJ mice were also sig-
niﬁ  cantly increased compared to C3H/HeJ wild-
type mice (79 ± 0.1 versus 28 ± 0.1 ug/dl, 
p = 0.006), and the peak emission ﬂ  uorescence 
was at 604 nm, characteristic of protoporphyrin. 
Thus, there was increased production and excre-
tion of protoporphyrin in the heterozygous C3H/
HeJ mice.
The levels of normal FECH mRNA in bone 
marrow and liver of wildtype C3H/HeJ mice were 
approximately 50% of those in CBA/J wildtype 
mice (Table 3), which agreed well with the relative 
levels estimated by relative quantitative PCR 
(Table 1). The lowest levels of normal FECH 
mRNA were found in C3H/HeJ heterozygous mice, 
in which bone marrow and liver levels were 
reduced by 57% and 60% respectively compared 
to levels in wildtype C3H/HeJ mice.
FECH enzyme activity in livers of heterozygous 
C3H/HeJ mice was reduced by 53% compared to 
the activity in wildtype C3H/HeJ mice, in parallel 
with the reduction in normal liver FECH mRNA. 
This argues against a signiﬁ  cant dominant/negative 
effect of the mutant FECH protein on the normal 
protein in mice with an exon 10 deletion. If that 
were the case, the reduction in FECH enzyme 
activity should have been approximately 75%.
In order to compare bone marrow expression of 
other genes in these two mouse strains, and poten-
tially to identify candidate modifier genes of 
FECH, DNA microarray analysis was done in adult 
male CBA/J and C3H/HeJ mice. This identiﬁ  ed 
103 genes that were upregulated in CBA/J mice 
compared to C3H/HeJ mice as deﬁ  ned by at least 
a 1.5 fold increase in mRNA level (p   0.05) 
(Table 4). There were 31 genes which had more 
than a two-fold change in the level of expression. 
In contrast there were only 48 bone marrow genes 
that were upregulated in C3H/HeJ mice compared 
to the CBA/J mice, six of which had a more than 
two-fold change in level of expression (Table 5). 
Thus more bone marrow genes in CBA/J mice are 
upregulated than in the C3H/HeJ mice. The path-
ways that were most impacted by these changes 
were SAPK-JNK signaling, mitrochondrial apop-
tosis control, integrin signaling, death receptor 
signaling, caspase signaling, apoptosis, PDGF 
signaling. The genes encoding other enzymes of 
Table 3. Normal FECH mRNA and FECH activity in 
mice.
 C3H/HeJ  +/− C3H/HeJ +/+ CBA/J +/+
FECH mRNA*     
bone marrow  138 ± 30  320 ± 59  634 ± 38
relative value  1.0  2.3  4.6
liver 430  ± 60  1078 ± 67  1798 ± 149
relative value  1.0  2.5  4.2
FECH activity**     
liver 4.4  ± 0.4  9.4 ± 0.2  10.8 ± 0.2
n 5  6  6
*copies/µg total RNA, mean ± SEM.
**pmol Zn-deuteroporphyrin per second per mg protein, mean ± SEM.
Table 2. Normal FECH mRNA and FECH activity in mice.237
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Table 4. Bone marrow genes upregulated in CBA/J mice compared to C3H/HeJ mice (mean fold change  1.5, 
P   0.05).
Gene title Fold Gene title Fold Gene title Fold
immunoglobulin heavy 
chain 1a (serum IgG2a)
26.5 RIKEN cDNA 
4930519L02 gene
2.3 caspase 3 1.9
Immunoglobulin heavy 
chain (gamma 
polypeptide)
8.5 SMC (structural mainte-
nance of chromosomes 
1)-like 1 (S. cerevisiae)
2.3 platelet-activating factor 
acetylhydrolase, isoform 
1b, alpha2 subunit
1.9
Immunoglobulin heavy 
chain (gamma 
polypeptide)
7.6 jumonji, AT rich 
interactive domain 1D 
(Rbp2 like)
2.3 ADP-ribosylation factor 
guanine nucleotide-
exchange factor 1
1.9
Son cell proliferation 
protein (Son), transcript 
variant 2, mRNA
6.2 thyroid hormone 
receptor interactor 12
2.3 src homology 2 domain-
containing transforming 
protein C1
1.9
Phosphofurin acidic 
cluster sorting protein 1 
(Pacs1), mRNA
3.5 RIKEN cDNA 
9430041J06 gene
2.3 carnitine palmitoyltrans-
ferase 1a, liver
1.9
immunoglobulin kappa 
chain variable 28 (V28) 
/// similar to immunoglob-
ulin light chain variable 
region
2.9 RIKEN cDNA 
1810060J02 gene
2.3 RIKEN cDNA 
2610005L07 gene
1.9
expressed sequence 
AI314760
2.8 Zinc ﬁ  nger, SWIM 
domain containing 6, 
mRNA (cDNA clone 
MGC:29327 
IMAGE:5025391)
2.2 sorcin 1.9
glia maturation factor, 
beta
2.6 high density lipoprotein 
(HDL) binding protein
2.1 choline kinase alpha 1.9
RNA binding motif 
protein 5
2.6 RIKEN cDNA 
9030612M13 gene
2.0 zinc ﬁ  nger, SWIM 
domain containing 6
1.8
EPM2A (laforin) 
interacting protein 1
2.5 RIKEN cDNA 
2610005L07 gene
2.0 RIKEN cDNA 
4932438A13 gene
1.8
expressed sequence 
AI585793
2.5 thyroid hormone 
receptor interactor 12
2.0 RIKEN cDNA 
2010106G01 gene
1.8
adaptor-related protein 
complex 3, mu 1 subunit
2.4 RIKEN cDNA 
2610005L07 gene
2.0 v-crk sarcoma virus 
CT10 oncogene 
homolog (avian)-like
1.8
T-cell leukemia 
translocation altered 
gene, mRNA (cDNA 
clone MGC:25540 
IMAGE:3672301)
2.4 vacuolar protein 
sorting 35
2.0 hook homolog 3 
(Drosophila)
1.8
expressed sequence 
AA407175
2.4 male sterility domain 
containing 2
2.0 acidic (leucine-rich) 
nuclear phosphoprotein 
32 family, member A
1.8
thyroid hormone receptor 
associated protein 3
2.4 alpha thalassemia/
mental retardation 
syndrome X-linked 
homolog (human)
2.0 chitobiase, di-N-acetyl- 1.8
GPI-anchored membrane 
protein 1
2.4 protein kinase, cAMP 
dependent, catalytic, 
beta
2.0 cDNA sequence 
BC021438
1.8
(Continued)238
Bloomer et al
Gene Regulation and Systems Biology 2008:2 
Table 4. (Continued).
Gene title Fold Gene title Fold Gene title Fold
expressed sequence 
AW011752
2.4 pinin 2.0 tripeptidyl peptidase II 1.8
RIKEN cDNA 
2610018G03 gene
2.3 Toll-like receptor 4, 
mRNA (cDNA clone 
MGC:35879 
IMAGE:3493732)
1.9 lipoma HMGIC fusion 
partner-like 2
1.8
expressed sequence 
AI316828
2.3 PREDICTED: histo-
compatibility 60 [Mus 
musculus], mRNA 
sequence
1.9 syntaxin 18 1.7
glia maturation factor, 
beta
2.3 RIKEN cDNA 
4933439C20gene
1.9 procollagen, type IV, 
alpha 3 (Goodpasture 
antigen) binding 
protein
1.7
RIKEN cDNA 
6230424C14 gene
1.7 PQ loop repeat contain-
ing
1.6
establishment of cohe-
sion 1 homolog 1 (S. 
cerevisiae)
1.7 CWF19-like 2, cell 
cycle control (S. 
pombe)
1.6
tetratricopeptide repeat 
domain 14
1.7 potassium channel 
tetramerisation domain 
containing 12b
1.6
Atpase, class VI, type 
11C
1.7 solute carrier family 26, 
member 8
1.6
Baculoviral IAP repeat-
containing 4 (Birc4), 
mRNA
1.7 Protein kinase C, alpha 
(Prkca), mRNA
1.6
RIKEN cDNA 
2810474O19 gene
1.7 fusion, derived from 
t(12;16) malignant 
liposarcoma (human)
1.6
Ndrp mRNA for neuronal 
differentiation related 
protein
1.7 zinc ﬁ  nger protein 146 1.6
WD repeat domain 48 1.7 retinol binding protein 
4, plasma
1.6
RIKEN cDNA 
4931406H21 gene
1.7 RIKEN cDNA 
3300001M20 gene
1.6
RIKEN cDNA 
1110059P08 gene 
(1110059P08Rik), mRNA
1.7 ubiquitin speciﬁ  c 
peptidase 3
1.6
ectonucleotide pyrophos-
phatase/phosphodiester-
ase 5
1.7 expressed sequence 
AW011752
1.6
Period homolog 3 (Dro-
sophila) (Per3), mRNA
1.7 inﬂ  uenza virus NS1A 
binding protein
1.6
SEC24 related gene 
family, member B (S. 
cerevisiae) (Sec24b), 
mRNA
1.7 transient receptor 
potential cation chan-
nel, subfamily M, 
member 7
1.6
(Continued)239
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the heme biosynthesis pathway showed no sig-
niﬁ  cant difference in level of expression between 
C3H/HeJ mice and CBA/J mice.
Discussion
This study demonstrates that mice strains have dif-
ferent levels of FECH mRNA in the major tissues of 
heme formation, bone marrow and liver, as CBA/J 
mice had levels approximately two times those found 
in C3H/HeJ mice (Tables 1 and 3). As a consequence, 
C3H/HeJ mice heterozygous for an exon 10 deletion 
in FECH had a signiﬁ  cantly higher level of protopor-
phyrin in erythrocytes and bile than wildtype C3H/
HeJ mice (Table 2), with an insigniﬁ  cant increase in 
heterozygous CBA/J mice compared to wild-type 
CBA/J mice. Thus, the level of expression of the 
nonmutant FECH allele is a determinant of bio-
chemical phenotype in this mouse model of EPP.
However, the biochemical abnormality in C3H/
HeJ heterozygous mice is mild compared to that 
in humans with clinically manifest EPP, where 
erythrocyte protoporphyrin levels are usually 
several hundred ug/dL, and in patients with severe 
disease several thousand ug/dL. In most humans 
with clinically manifest EPP, the level of expression 
of the nonmutant FECH allele is lowered by a 
polymorphism in intron 3 (IVS3-48c) that causes 
increased formation of aberrantly spliced FECH 
mRNA due to activation of a cryptic acceptor 
splice site. This causes incorporation of 63 bases 
of intron 3 into FECH mRNA, and the aberrantly 
spliced transcript contains a stop codon that causes 
it to be rapidly degraded by nonsense mediated 
decay. Thus the polymorphism exerts a more 
pronounced effect on the expression of the 
nonmutant FECH allele than occurs due to 
baseline expression in the mouse model. 
Table 4. (Continued).
Gene title Fold Gene title Fold Gene title Fold
nuclear receptor subfam-
ily 2, group C, member 2
1.6 v-crk sarcoma virus 
CT10 oncogene 
homolog (avian)
1.6
ubiquitin speciﬁ  c pepti-
dase 34
1.6 poly (A) polymerase 
alpha
1.5
5’-nucleotidase, cytosolic 
II-like 1
1.6 AF4/FMR2 family, 
member 1
1.5
CCR4-NOT transcription 
complex, subunit 7
1.6 inhibitor of kappa light 
polypeptide enhancer 
in B-cells, kinase 
complex-associated 
protein
1.5
ROD1 regulator of 
differentiation 1 
(S. pombe)
1.6 PREDICTED: Braf 
transforming gene [Mus 
musculus], mRNA 
sequence
1.5
tripartite motif protein 30 1.6 phosphatase and 
tensin homolog
1.5
MARVEL (membrane-
associating) domain 
containing 1
1.6
solute carrier family 2 
(facilitated glucose 
transporter), member 9
1.6
RIKEN cDNA 
0610010K06 gene
1.6
Wiskott-Aldrich syn-
drome protein interacting 
protein (Waspip), mRNA
1.6240
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Table 5. Bone marrow genes upregulated in C3H/HeJ mice compared to CBA/J mice (mean fold change  1.5, 
P   0.05).
Gene title Fold Gene title Fold
complement receptor 2 2.3 protein kinase C, epsilon 1.6
chemokine (C-C motif) receptor 6 2.3 B-cell leukemia/lymphoma 2 1.6
Fas apoptotic inhibitory molecule 3 2.2 RIKEN cDNA 9230115F04 gene 1.6
GTPase, IMAP family member 7 2.1 phenylalanine-tRNA synthetase-like, 
beta subunit
1.6
Phosphatidic acid phosphatase type 
2B (Ppap2b), mRNA
2.0 pleckstrin homology domain-containing, 
family A (phosphoinositide binding 
speciﬁ  c) member 2
1.6
SH3-binding kinase 1 2.0 EMI domain containing 1 1.6
zinc ﬁ  nger protein 318 2.0 N-acetylglutamate synthase 1.6
phosphorylase kinase alpha 1 2.0 histocompatibility 2, O region alpha 
locus
1.6
chemokine (C-C motif) receptor 7 1.9 RIKEN cDNA 6430596G11 gene 1.6
CD22 antigen 1.9 caspase recruitment domain family, 
member 11
1.6
A kinase (PRKA) anchor protein 2 1.9 POU domain, class 2, transcription 
factor 2
1.6
AF4/FMR2 family, member 3 (Aff3), 
mRNA
1.8 Forkhead box P1 (Foxp1), mRNA 1.6
hypothetical protein A630043P06 1.8 ankyrin repeat domain 10 1.6
T-cell receptor alpha chain /// RIKEN 
cDNA A430107P09 gene
1.8 expressed sequence AW742319 1.5
RIKEN cDNA 2310051N18 gene 1.8 gene model 1752, (NCBI) 1.5
radical S-adenosyl methionine domain 
containing 1
1.8 hemoglobin Y, beta-like embryonic chain 1.5
RIKEN cDNA 4921511H13 gene 1.7 SEC8 (S. cerevisiae), mRNA (cDNA 
clone MGC:36178 IMAGE:5355276)
1.5
PREDICTED: similar to cyclin B1 
interacting protein 1 isoform a [Mus 
musculus], mRNA sequence
1.7 brain protein 16 1.5
TRNA splicing endonuclease 2 homo-
log (SEN2, S. cerevisiae) (Tsen2), 
mRNA
1.7 RIKEN cDNA 2700094F01 gene, mRNA 
(cDNA clone MGC:73433 
IMAGE:6400080)
1.5
zinc ﬁ  nger and BTB domain contain-
ing 4
1.7 RIKEN cDNA 1810013B01 gene 1.5
Myocyte enhancer factor 2C, mRNA 
(cDNA clone MGC:46981 
IMAGE:4500786)
1.7 Pyruvate dehydrogenase kinase, isoen-
zyme 1, mRNA (cDNA clone MGC:28719 
IMAGE:4458562)
1.5
ﬁ  bromodulin 1.7 DEAD (Asp-Glu-Ala-Asp) box polypep-
tide 54
1.5
sestrin 3 1.7 lymphocyte protein tyrosine kinase 1.5
cDNA sequence BC066028 1.6 methylenetetrahydrofolate 
dehydrogenase (NAD+ dependent), 
methenyltetrahydrofolate cyclohydrolase
1.5241
Level of expression of the nonmutant ferrochelatase allele is a determinant of biochemical phenotype
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Nevertheless, among patients who carry the same 
mutation and the polymorphism there can be 
considerable variation in the severity of the 
phenotype, thus indicating that there are probably 
additional factors outside the FECH locus that 
impact phenotype in EPP, in particular transcription 
factors and modiﬁ  er genes that might alter the 
level of expression of FECH. There are several 
other bone marrow genes in CBA/J mice that are 
differently regulated than those in C3H/HeJ mice 
(Tables 4 and 5). Which, if any, of these might be 
causing a difference in FECH expression cannot 
be determined at this time, however.
Several other investigators reported that the 
phenotype of a single mutation in mice was 
modulated by the genetic background of the 
strain, which was attributed to modiﬁ  er genes 
(Montagutelli, 2000). This includes the ethylnitro-
sourea-induced point mutation in FECH that was 
originally described as causing recessive inheri-
tance of FECH activity in the house mouse 
(FECH
ml/Pas/FECH 
ml/Pas mouse) (Boulechfar et al. 
1993). Abitbol et al. examined three congenic 
strains into which the point mutation had been 
introduced (Abitol et al. 2005). Compared with the 
BALB/cByJCrl genetic background in which 
recessive transmission of the mutation caused 
severe skin lesions, anemia, jaundice and hepatic 
dysfunction with massive protoporphyrin deposits, 
C57BL/6JCrl mice developed anemia and intense 
liver accumulation of protoporphyrin with hepato-
cyte damage, but bile excretory function was not 
affected, and the serum bilirubin remained low. In 
SJL/JOrlCrl homozygous mice there was a very high 
protoporphyrin concentration in erythrocytes, but 
anemia was mild, and there were few hepatic depos-
its. Navarro et al. used these same three congenic 
strains to show a difference in the level of mitochon-
drial respiratory chain enzyme activities and sug-
gested that an increase of these activities provided 
protection against liver disease in the EPP mice 
(Navarro et al. 2005). Thus, the study of different 
congenic mice strains with EPP may provide a means 
by which to identify modiﬁ  er genes of phenotype in 
this disorder, which could help in understanding the 
reason for different phenotypes in human EPP.
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